Waters New HILIC-based Glycoprotein Column Enhances Glycan Analysis

Waters Corporation (NYSE:WAT) introduced a new ACQUITY UPLC® Glycoprotein BEH Amide 300Å 1.7-µm Column enabling biopharmaceutical companies to better understand where glycan molecules are located within the therapeutic proteins they are developing. Identifying the precise location of glycans within a protein structure is essential to delivering safe and effective biotherapeutic proteins.

The novel, patent-pending ACQUITY BEH Amide technology, assists scientists in obtaining reproducible glycan-related chromatographic and mass spec information at the intact protein, fragment, or peptide levels. Designed to be used with Waters ACQUITY UPLC systems, this new glycoprotein analysis column provides unprecedented resolution using MS-compatible HILIC separations. Laboratories can now resolve different glycoproteins and glycopeptides, determine where both Nlinked and O-linked glycans are located within the protein, as well as better understand glycan modifications and patterns. Combining these capabilities with mass spectrometric analysis provides far greater information about glycoprotein structure than has been previously available.

“Waters has been leading the way in innovative solutions for glycan analysis to help our biopharmaceutical customers solve the challenges they face with their traditional glycan workflows. The new ACQUITY UPLC Glycoprotein BEH Amide Column, joins a family of market leading disruptive technologies, including our Glycan Application Solution with UNIFI® for characterization, and our most recent GlycoWorks™ RapiFluor-MS™ N-Glycan sample preparation kits,” said Mike Yelle, Vice President of Waters’ Consumable Business Unit.

“Released glycan profiling using our GlycoWorks™ RapiFluor-MS™ kits provides essential information about the types of glycans present, and now the ACQUITY UPLC® Glycoprotein BEH Amide column enables scientists to readily determine where these glycans are located within the protein structure. While this can be relatively simple for monoclonal antibodies, it can be very complicated and critical for complex proteins. The development of our new column technology offers easy access to this information for both N- and O-linked glycans, and allows organizations to consider adding this critical analysis into their routine glycan workflows.”

The ACQUITY UPLC Glycoprotein BEH Amide column is quality control tested and shipped with a Glycoprotein Test Standard, further emphasizing Waters’ drive to quality, consistency, and standardization.

The column will be available for sale globally in July, 2015, and comes in a variety of formats:

• ACQUITY UPLC Glycoprotein BEH Amide 300Å, 1.7-µm, 2.1 x 5 mm Guard, 3/pkg with Standard (P/N 176003699)
• ACQUITY UPLC Glycoprotein BEH Amide 300Å, 1.7-µm, 2.1 x 50 mm with Standard (P/N 176003700)
• ACQUITY UPLC Glycoprotein BEH Amide 300Å, 1.7-µm, 2.1 x 100 mm with Standard (P/N 176003701)
• ACQUITY UPLC Glycoprotein BEH Amide 300Å, 1.7-µm, 2.1 x 150 mm with Standard (P/N 176003702)
• ACQUITY UPLC Glycoprotein BEH Amide 300 Å, 1.7-µm, 2.1 x 100 MVK, 3/pkg with Standard (P/N 176003703)
• Glycoprotein Performance Test Standard (P/N 186008010)

For more news on ASMS 2015 please click here.